Work

Abstract P2-01-02: Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant Olaparib

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs22-p2-01-02

Authors: Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A. Mittendorf, Tari King, Anna Weiss, Ann Partridge, Brittany Bychkovsky, Giuseppe Curigliano, Nabihah Tayob, Nancy U. Lin, Judy Garber, Sara Tolaney, Filipa Lynce

Institutions: Broad Institute, Harvard University, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, Alliance Foundation Trials, European Institute of Oncology

Language: English

Topic: BRCA gene mutations in cancer

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4322774339

Cites:

Cited by:

Related to: 10